Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 8,25 M
EBIT 2016 2,53 M
Net income 2016 2,52 M
Debt 2016 -
Yield 2016 -
Sales 2017 17,2 M
EBIT 2017 11,7 M
Net income 2017 8,13 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 12,11
P/E ratio 2017 4,95
Capi. / Sales2016 4,20x
Capi. / Sales2017 2,02x
Capitalization 34,7 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar
11/09Earnings Release
More about the company
Latest news on INTELGENX TECHNOLOGIES COR
07/13 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
07/13 INTELGENX TECHNOLOGIES : to Initiate Phase 1 Trial of Montelukast
07/13 INTELGENX TECHNOLOGIES : to Initiate Phase 1 Trial of Montelukast
07/12 INTELGENX TECHNOLOGIES : Announces notice of appeal for buprenorphine and naloxo..
07/11 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
07/11 INTELGENX TECHNOLOGIES : Announces Notice of Appeal for Buprenorphine/Naloxone S..
07/11 INTELGENX TECHNOLOGIES : Announces Notice of Appeal for Buprenorphine/Naloxone S..
07/05 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
07/05 INTELGENX TECHNOLOGIES : and RedHill Biopharma Announce Signing of Definitive Ag..
05/12 INTELGENX TECHNOLOGIES : Reports Amendment of Stock Option Plan
More news
Sector news : Generic Pharmaceuticals
08:48aDJMERCK : Earnings Watch -- WSJ
01:14a BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
More sector news : Generic Pharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 175%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Horst G. Zerbe Chairman, President & Chief Executive Officer
André Godin Chief Financial Officer & Executive Vice President
Nadine Paiement Director-Research & Development
Bernd Josef Melchers Independent Director
John Archibald Troup Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INTELGENX TECHNOLOGIES..35
SUN PHARMACEUTICAL IND..0.63%29 924
OTSUKA HOLDINGS CO LTD12.90%26 741
ONO PHARMACEUTICAL CO...-14.28%21 372
BIOMARIN PHARMACEUTICA..-5.10%16 138
ASPEN PHARMACARE HOLDI..22.89%12 289
More Results